Zosano Pharma Corp (ZSAN.OQ)
23 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2017||Chairman of the Board, President, Chief Executive Officer|
|49||2016||Interim Chief Financial Officer, Chief Business Officer|
|2015||Vice President - Technical Operations|
|2015||Chief Medical Officer|
- BRIEF-Zosano Reaches Enrollment Milestone In M207-Adam Long-Term Safety Study
- BRIEF-Zosano Pharma Reports Q4 Loss Per Share $3.80
- BRIEF-Zosano Pharma Announces Issuance Of New U.S. Patent Covering M207 As An Acute Treatment For Migraine
- BRIEF-Zosano Pharma Files Prospectus Related Offering 12.5 Mln Shares
- BRIEF-Zosano Pharma Files Prospectus Related To 10 Mln Stock Offering